|Cardiovascular and Metabolic Market|
Cardiovascular and Metabolic Market Forecast
Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2019, with growth driven by a rich pipeline and new drug classes. Thrombosis has stable sales; however, the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market decreasing by -0.5% in the seven major markets.
The cardiovascular and metabolic market is forecast to peak in 2011, and total market revenues will record a negative compound annual growth rate (CAGR) of -0.5% between 2009 and 2019. This is despite forecast growth in the volume consumption of cardiovascular and metabolic drugs at a CAGR of 1.8% over the same period.
Antidiabetic therapies are forecast to become the highest revenue generators in 2019, contributing 35% of all sales in the seven major markets and 50% of cardiovascular and metabolic sales in the key US market, where other therapy areas are highly eroded by genericization.
Merck & Co. is forecast to be the leading cardiovascular and metabolic company by 2019, driven by its blockbuster antidiabetic Januvia franchise. Novo Nordisk will grow to take second spot in 2019 due to its focus on insulin therapies and peptides that are more resistant to generic competition.
Newer news items
|< Prev||Next >|
Monitoring comments about specific product
You can easily monitor comments about offer and demand specifically interesting for you. On the Comments bar (below main article) click on the RSS button and bookmark this RSS feed.